Philippines

Population 2018 107 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>591 (332–924)</td>
<td>554 (311–866)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>10 (4.1–19)</td>
<td>9.4 (3.8–17)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>18 (7.7–32)</td>
<td>17 (7.3–30)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>26 (22–30)</td>
<td>24 (20–28)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.6 (0–4.2)</td>
<td>0.57 (0–4)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- New cases: 1.7% (1.1–2.5)
- Previously treated cases: 16% (19–20)

TB case notifications, 2018
Total new and relapse: 371,668
- % tested with rapid diagnostics at time of diagnosis: 36%
- % with known HIV status: 27%
- % pulmonary: 98%
- % bacteriologically confirmed**: 36%
- % children aged 0–14 years: 12%
- % women: 30%
- % men: 58%
Total cases notified: 382,543

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018: 63% (40–110)
- TB patients facing catastrophic total costs, 2017: 35% (33–37)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 5% (3–7)

TB/HIV care in new and relapse TB patients, 2018
Number (%)
- % known HIV status who are HIV-positive: 1,477 (1%
- % on antiretroviral therapy: 1,350 (91%

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance**:<1%
- % of MDR/RR-TB cases tested for resistance to second-line drugs: 2,095

Treatment success rate and cohort size
<table>
<thead>
<tr>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2017: 91%</td>
<td>315,923</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2017: 82%</td>
<td>9,466</td>
</tr>
<tr>
<td>HIV-positive TB cases registered in 2017: 83%</td>
<td>1,208</td>
</tr>
<tr>
<td>MDR/RR-TB cases started on second-line treatment in 2016: 58%</td>
<td>5,071</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2016: 20%</td>
<td>10</td>
</tr>
</tbody>
</table>

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment: 52%
- % of children (aged < 5) household contacts of bacteriologically-confirmed MDR/RR-TB: 9.4% (8.7–10)

TB financing, 2019
National TB budget (US$ millions): 205
Funding source: 12% domestic, 25% international, 63% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed